Plug-in hybrids are starting to find favour – and for good reason, given their inherent practicality, with more than a hint ...
Reported positive update from Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC, with the 30 mg onvansertib + FOLFIRI/bev arm demonstrating: ...
CagriSema achieved 23% weight loss after 84 weeks of treatmentCagriSema 2.4/2.4 mg did not meet the primary endpoint of showing non-inferiority on weight loss compared to tirzepatide 15 mg at 84 weeks ...
Morning Overview on MSN
Eli Lilly’s new Zepbound pen packs a full month of obesity doses
Eli Lilly and Company (NYSE: LLY) announced on February 23, 2026, that the U.S. Food and Drug Administration has approved a ...
MG Motor India appears to be preparing a significant addition to its SUV lineup, with a new plug-in hybrid SUV spotted ...
Feb 23 (Reuters) - Eli Lilly said on Monday it received the U.S. Food and Drug Administration's approval to launch a four-dose KwikPen for its weight-loss drug Zepbound, delivering a full month of the ...
Announced positive 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ― ...
The Maruti Suzuki e Vitara competes against models like the Hyundai Creta Electric, Mahindra BE6, and MG Windsor EV in India.
The FDA has approved a new four-dose, single-patient-use KwikPen for Zepbound (tirzepatide), giving patients a full month of treatment in one device.
JSW Motors has taken a bold step towards announcing its entry into India’s passenger vehicle space, placing a full front-page advertisement ...
Children with multiple nut allergies experienced significant increases in the amounts of allergens they could tolerate with ...
Fasinumab 1 mg every 4 weeks led to greater clinical improvements compared with naproxen or placebo in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results